StockMarketWire.com - Animalcare - a leading supplier of veterinary medicines - has been granted a marketing authorisation in a number of key European markets for injectable presentations of the large animal antibiotic marbofloxacin.

Animalcare will sell the product in the UK and through its distributors in France and Ireland under the brand name Marbocare.

Marbocare is an addition to Animalcare's range of large animal products and is used primarily in cattle and pigs for the treatment of mastitis and respiratory diseases.

In 2011 the UK market for injectable forms of marbofloxacin was worth approximately £2.2m per annum.

Marbocare is another example of successful collaboration between Animalcare and European partners, this being a joint development with a Belgium partner.

The group has targeted the launch of four new veterinary medicines during the year and following on from the launch of Vitofyllin in September 2012, Marbocare injections will now be the second product launched in the current financial year.

Chief executive Stephen Wildridge said: "We are very pleased that we will shortly be able to bring our second new veterinary medicine to the market in this financial year.

"Marbocare injections will be a useful addition to our growing and more modern range of treatments for diseases of livestock which will add impetus to our efforts in this market."


At 8:19am: [LON:ANCR] share price was 0p at 138p



Story provided by StockMarketWire.com